Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ), a pharmaceutical company provides the development and commercialization of orphan drugs in Sweden and globally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. Incorporated in 2006 and headquartered in Stockholm, Sweden, Egetis Therapeutics AB (publ) was formerly known as PledPharma AB (publ) before rebranding in December 2020.